[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353004-105":59,"doc-detail-353004-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","from-cell-lines-to-the-clinic-identifying-a-urinary-blca-ev-signature-through-comparative-proteomics-of-bladder-cancer-lysates-and-extracellular-vesicles","From cell lines to the clinic - identifying a urinary BlCa-EV signature through comparative proteomics of bladder cancer lysates and extracellular vesicles","","Bladder cancer management urgently needs improved diagnostic and therapeutic strategies due to high incidence, mortality, and morbidity. Extracellular vesicles (EVs) are promising biomarker candidates because their cargo is protected from degradation and they can be isolated non-invasively from urine. EVs also drive intercellular communication that shapes disease progression, supporting their use in tailored therapy approaches.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/from-cell-lines-to-the-clinic-identifying-a-urinary-blca-ev-signature-through-comparative-proteomics-of-bladder-cancer-lysates-and-extracellular-vesicles/353004/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/from-cell-lines-to-the-clinic-identifying-a-urinary-blca-ev-signature-through-comparative-proteomics-of-bladder-cancer-lysates-and-extracellular-vesicles/353004.png","ImageObject",300,407,{"name":92,"@type":93},"Stanford","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are extracellular vesicles (EVs) considered promising biomarkers for bladder cancer?","Question",{"text":112,"@type":113},"Their cargo is protected from degradation and EVs can be isolated non-invasively from urine. They also participate in intercellular communication that drives disease progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the bladder cancer EV signature identified in this study?",{"text":117,"@type":113},"High-throughput mass spectrometry was used for comprehensive proteomic analysis of bladder cancer cell lysates and matched EVs. EVs from six human BlCa cell lines were analyzed to define a BlCa-associated signature.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find in urinary EV samples from patients and controls?",{"text":121,"@type":113},"The researchers validated a robust and novel 13-protein BlCa-enriched urinary EV signature, including ITGA2, ITGA6, SCRIB, and TFRC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353004,1790928776,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Lourenço etal. Cell Communication and Signaling (2026) 24:317  \n[https://doi.org/10.1186/s12964-026-02868-2](https://doi.org/10.1186/s12964-026-02868-2)  \nCell Communication and Signaling  \nRESEARCH Open Access  \nFrom cell lines to the clinic: identifying a urinary BlCa-EV signature through comparative proteomics of bladder cancer lysates and extracellular vesicles  \nCatarina Lourenço 1,2,3,4, Vera Constâncio1,2, Nuno Tiago Tavares1,2,3, Sara Monteiro-Reis1,2, Rui Silva-Santos1,5, João Lobo1,2,5, Ângela Carvalho4,6 and Carmen Jerónimo1,2,7*  \nAbstract  \nBackground There is an urgent need for the development of innovative diagnostic and therapeutic strategies in bladder cancer (BlCa) management, due to its significant incidence, mortality, and morbidity. Extracellular vesicles (EVs) constitute promising candidates as biomarkers, as their cargo is highly protected from degradation, and they can be isolated non-invasively from urine. Furthermore, they play a pivotal role in intercellular communication that drives disease progression, making them suitable candidates for tailored therapy approaches.  \nMethods We employed high-throughput mass-spectrometry to perform a comprehensive proteomic analysis of cell lysates and matched EVs. EVs were isolated from six distinct human BlCa cell lines, representatives of the complete disease spectrum, to identify a BlCa-EV associated signature. The translational ability of this signature was analyzed in urinary EV (uEV) samples from BlCa patients and healthy controls.  \nResults This study established a new lysate-to-EV signature that is common to all malignant cell lines. Afterwards, this profile was analyzed in BlCa uEVs, identifying a robust and novel 13-protein BlCa-enriched signature, which includes ITGA2, ITGA6, SCRIB, and TFRC.  \nConclusion We unveiled a novel, EV-derived protein signature that has potential to be further applied for future functional studies, non-invasive diagnostic assays and targeted therapeutic interventions against BlCa.  \nKeywords Bladder cancer, Extracellular vesicles, Cell lines, Proteomics, Urine  \n*Correspondence:  \nCarmen Jerónimo [carmenjeronimo@ipoporto.min-saude.pt](carmenjeronimo@ipoporto.min-saude.pt)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nLourenço et al. Cell Communication and Signaling (2026) 24:317 Page 2 of 20  \nGraphical Abstract  \nIntroduction  \nBladder cancer (BlCa) is among the 10 most common cancers in the world [1], presenting a significant health burden due to increasing incidence and mortality rates, coupled with the limitations of current diagnostic and monitoring approaches [2]. While non-muscle-invasive bladder cancer (NMIBC) often carries a favorable prognosis, it presents high recurrence and progression rates to muscle invasive disease [3]. Consequently, these patients are subject","cbCaiuYHGyK4jJ2A","https://ap.wps.com/l/cbCaiuYHGyK4jJ2A","pdf",3972107,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"Why are extracellular vesicles (EVs) considered promising biomarkers for bladder cancer?\",\"answer\":\"Their cargo is protected from degradation and EVs can be isolated non-invasively from urine. They also participate in intercellular communication that drives disease progression.\"},{\"question\":\"How was the bladder cancer EV signature identified in this study?\",\"answer\":\"High-throughput mass spectrometry was used for comprehensive proteomic analysis of bladder cancer cell lysates and matched EVs. EVs from six human BlCa cell lines were analyzed to define a BlCa-associated signature.\"},{\"question\":\"What did the study find in urinary EV samples from patients and controls?\",\"answer\":\"The researchers validated a robust and novel 13-protein BlCa-enriched urinary EV signature, including ITGA2, ITGA6, SCRIB, and TFRC.\"}]","From cell lines to the clinic - identifying a urinary BlCa-EV signature through comparative proteomics of bladder cancer lysates and extracellular vesicles | PDF",1790102540,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/121c4aa980bda5f426e6926d07860b9c.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e385b74d8499689fbf857b00bd5907ce.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de5f5402572142f37abc0df54d9a3fe5.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/390b1b52ba5775694fd06f6ec90c43c1.webp",980,1306]